| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.403 | 0.026 | 0.451 | Superoxide dismutase inhibitor | 0.451 0.019 DBMET02368 | DBMET02368 | |
| 0.394 | 0.032 | 0.394 | Interleukin antagonist | 0.341 0.04 DBMET02368 | ||
| 0.402 | 0.045 | 0.71 | 5 Hydroxytryptamine release stimulant | 0.71 0.006 DBMET02368 | DBMET02368 | |
| 0.365 | 0.037 | 0.365 | DNA damaging | 0.225 0.097 DBMET02368 | ||
| 0.356 | 0.032 | 0.356 | Insulysin inhibitor | 0.354 0.033 DBMET02368 | ||
| 0.334 | 0.029 | 0.334 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | |||
| 0.382 | 0.085 | 0.382 | Antibacterial | 0.305 0.131 DBMET02368 | ||
| 0.336 | 0.066 | 0.336 | Streptokinase A inhibitor | |||
| 0.273 | 0.005 | 0.273 | Falcipain 3 inhibitor | 0.197 0.018 DBMET02368 | ||
| 0.315 | 0.064 | 0.315 | Interleukin 2 agonist | |||
| 0.262 | 0.019 | 0.262 | Neurotensin receptor agonist | 0.216 0.028 DBMET02368 | ||
| 0.333 | 0.095 | 0.333 | Calpain 2 inhibitor | |||
| 0.234 | 0.004 | 0.234 | 5 Hydroxytryptamine 2A agonist | 0.083 0.025 DBMET02368 | ||
| 0.301 | 0.078 | 0.301 | Caspase 3 stimulant | 0.244 0.118 DBMET02368 | ||
| 0.249 | 0.049 | 0.249 | Sigma receptor agonist | 0.221 0.055 DBMET02368 | ||
| 0.342 | 0.144 | 0.342 | Apoptosis agonist | 0.339 0.145 DBMET02368 | ||
| 0.248 | 0.05 | 0.248 | Platelet adhesion inhibitor | |||
| 0.231 | 0.039 | 0.231 | Thrombolytic | 0.137 0.092 DBMET02368 | ||
| 0.245 | 0.061 | 0.245 | Neuropeptide Y2 antagonist | |||
| 0.189 | 0.006 | 0.195 | Myeloperoxidase inhibitor | 0.195 0.005 DBMET02368 | DBMET02368 | |
| 0.173 | 0.005 | 0.173 | Maillard reaction inhibitor | |||
| 0.179 | 0.014 | 0.179 | Nitric-oxide synthase inhibitor | |||
| 0.185 | 0.023 | 0.185 | Nav1.4 sodium channel blocker | 0.101 0.074 DBMET02368 | ||
| 0.227 | 0.065 | 0.227 | Amyloid beta aggregation inhibitor | 0.201 0.077 DBMET02368 | ||
| 0.215 | 0.053 | 0.215 | Growth hormone agonist | 0.13 0.107 DBMET02368 | ||
| 0.238 | 0.084 | 0.541 | Aryl hydrocarbon receptor agonist | 0.541 0.02 DBMET02368 | DBMET02368 | |
| 0.24 | 0.086 | 0.316 | 5 Hydroxytryptamine 1E antagonist | 0.316 0.021 DBMET02368 | DBMET02368 | |
| 0.23 | 0.079 | 0.23 | Angiogenesis stimulant | 0.185 0.102 DBMET02368 | ||
| 0.158 | 0.01 | 0.158 | Interleukin 12 antagonist | 0.106 0.045 DBMET02368 | ||
| 0.237 | 0.091 | 0.237 | Antioxidant | 0.202 0.112 DBMET02368 | ||
| 0.179 | 0.034 | 0.211 | Toll-Like receptor 2 antagonist | 0.211 0.019 DBMET02368 | DBMET02368 | |
| 0.248 | 0.104 | 0.248 | Ca(v)3.3 blocker | |||
| 0.225 | 0.085 | 0.225 | Platelet antagonist | |||
| 0.152 | 0.012 | 0.152 | Neuropeptide agonist | |||
| 0.137 | 0.004 | 0.137 | S-adenosyl-L-methionine decarboxylase inhibitor | |||
| 0.19 | 0.057 | 0.19 | Anticoagulant | |||
| 0.177 | 0.05 | 0.177 | Thiol protease inhibitor | |||
| 0.141 | 0.015 | 0.141 | 5 Hydroxytryptamine 1 agonist | 0.089 0.023 DBMET02368 | ||
| 0.179 | 0.052 | 0.188 | Melanin inhibitor | 0.188 0.046 DBMET02368 | DBMET02368 | |
| 0.213 | 0.088 | 0.23 | Free radical scavenger | 0.23 0.078 DBMET02368 | DBMET02368 | |
| 0.218 | 0.097 | 0.218 | Calpain inhibitor | |||
| 0.167 | 0.048 | 0.167 | Nav1.2 sodium channel blocker | |||
| 0.199 | 0.082 | 0.199 | Platelet aggregation inhibitor | 0.167 0.109 DBMET02368 | ||
| 0.157 | 0.041 | 0.157 | Antibacterial (Helicobacter pylori) | 0.142 0.053 DBMET02368 | ||
| 0.142 | 0.027 | 0.152 | Urease inhibitor | 0.152 0.022 DBMET02368 | DBMET02368 | |
| 0.168 | 0.056 | 0.168 | Lipid peroxidase inhibitor | |||
| 0.177 | 0.069 | 0.177 | Dual specificity phosphatase inhibitor | 0.177 0.069 DBMET02368 | ||
| 0.132 | 0.029 | 0.132 | Factor V inhibitor | |||
| 0.237 | 0.137 | 0.259 | Antithrombotic | 0.259 0.119 DBMET02368 | DBMET02368 | |
| 0.142 | 0.044 | 0.142 | MAO A inhibitor | |||
| 0.146 | 0.049 | 0.146 | Cathepsin H inhibitor | 0.11 0.089 DBMET02368 | ||
| 0.116 | 0.026 | 0.116 | Factor XII inhibitor | 0.076 0.075 DBMET02368 | ||
| 0.108 | 0.02 | 0.108 | 5 Hydroxytryptamine 1D antagonist | |||
| 0.132 | 0.046 | 0.144 | 5 Hydroxytryptamine 3A agonist | 0.144 0.039 DBMET02368 | DBMET02368 | |
| 0.085 | 0.005 | 0.085 | 5 Hydroxytryptamine 1D agonist | |||
| 0.11 | 0.029 | 0.11 | Inducible nitric-oxide synthase inhibitor | |||
| 0.123 | 0.043 | 0.123 | Falcipain inhibitor | |||
| 0.083 | 0.005 | 0.083 | Diamine oxidase inhibitor | |||
| 0.117 | 0.043 | 0.117 | Falcipain 2 inhibitor | |||
| 0.12 | 0.049 | 0.12 | Check point kinase 2 inhibitor | |||
| 0.118 | 0.048 | 0.243 | Beta glucuronidase inhibitor | 0.243 0.009 DBMET02368 | DBMET02368 | |
| 0.156 | 0.091 | 0.156 | Dual specificity phosphatase 3 inhibitor | 0.151 0.096 DBMET02368 | ||
| 0.126 | 0.061 | 0.126 | Proteasome inhibitor | |||
| 0.071 | 0.022 | 0.071 | 5 Hydroxytryptamine 1A agonist | |||
| 0.135 | 0.09 | 0.135 | Neuropeptide Y1 antagonist | |||
| 0.059 | 0.015 | 0.059 | Histamine H2 receptor agonist | |||
| 0.063 | 0.02 | 0.063 | Complement C3a chemotactic receptor antagonist | |||
| 0.154 | 0.112 | 0.357 | Pyruvate kinase inhibitor | 0.357 0.031 DBMET02368 | DBMET02368 | |
| 0.107 | 0.067 | 0.107 | DNA intercalator | |||
| 0.268 | 0.231 | 0.573 | Caspase 9 stimulant | 0.573 0.04 DBMET02368 | DBMET02368 | |
| 0.066 | 0.03 | 0.066 | Gonadotropin-releasing hormone receptor agonist | |||
| 0.058 | 0.022 | 0.058 | Sodium/calcium exchanger inhibitor | |||
| 0.145 | 0.11 | 0.373 | DNA methyltransferase I inhibitor | 0.373 0.011 DBMET02368 | DBMET02368 | |
| 0.082 | 0.049 | 0.113 | Somatostatin 1 agonist | 0.113 0.027 DBMET02368 | DBMET02368 | |
| 0.126 | 0.093 | 0.126 | Death-associated protein kinase 1 inhibitor | |||
| 0.15 | 0.122 | 0.15 | Death-associated protein kinase 3 inhibitor | 0.142 0.135 DBMET02368 | ||
| 0.065 | 0.043 | 0.065 | Neuraminidase (influenza) inhibitor | |||
| 0.191 | 0.168 | 0.26 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.26 0.097 DBMET02368 | DBMET02368 | |
| 0.09 | 0.069 | 0.099 | Toll-Like receptor 3 antagonist | 0.099 0.052 DBMET02368 | DBMET02368 | |
| 0.06 | 0.041 | 0.08 | Bombesin 1 receptor agonist | 0.08 0.025 DBMET02368 | DBMET02368 | |
| 0.098 | 0.08 | 0.222 | Protein kinase C gamma inhibitor | 0.222 0.01 DBMET02368 | DBMET02368 | |
| 0.036 | 0.018 | 0.11 | Melatonin receptor 1A agonist | 0.11 0.003 DBMET02368 | DBMET02368 | |
| 0.027 | 0.01 | 0.027 | Melatonin 3 antagonist | |||
| 0.139 | 0.123 | 0.313 | Lipocortins synthesis antagonist | 0.313 0.019 DBMET02368 | DBMET02368 | |
| 0.081 | 0.066 | 0.085 | Ornithine decarboxylase inhibitor | 0.085 0.061 DBMET02368 | DBMET02368 | |
| 0.092 | 0.077 | 0.092 | Nav1.1 sodium channel blocker | |||
| 0.099 | 0.085 | 0.099 | Electron transport complex I inhibitor | |||
| 0.123 | 0.109 | 0.167 | MAP3K9 inhibitor | 0.167 0.038 DBMET02368 | DBMET02368 | |
| 0.064 | 0.051 | 0.064 | 5 Hydroxytryptamine agonist | |||
| 0.03 | 0.018 | 0.03 | Melatonin antagonist | |||
| 0.068 | 0.057 | 0.068 | Thrombin inhibitor | |||
| 0.031 | 0.02 | 0.031 | Glucagon receptor antagonist | |||
| 0.033 | 0.022 | 0.044 | Melatonin agonist | 0.044 0.012 DBMET02368 | DBMET02368 | |
| 0.049 | 0.04 | 0.063 | 5 Hydroxytryptamine 4 antagonist | 0.063 0.022 DBMET02368 | DBMET02368 | |
| 0.027 | 0.018 | 0.027 | Melanocortin 1 agonist | |||
| 0.047 | 0.039 | 0.056 | Bombesin 2 receptor antagonist | 0.056 0.027 DBMET02368 | DBMET02368 | |
| 0.032 | 0.025 | 0.051 | Melatonin 1 agonist | 0.051 0.009 DBMET02368 | DBMET02368 | |
| 0.058 | 0.052 | 0.058 | Trypsin inhibitor | |||
| 0.053 | 0.048 | 0.053 | CXC chemokine 4 receptor antagonist | |||
| 0.038 | 0.034 | 0.038 | Melanocortin 4 antagonist | |||
| 0.034 | 0.03 | 0.034 | Melanocortin 1 antagonist | |||
| 0.042 | 0.04 | 0.042 | Melanocortin antagonist | |||
| 0.05 | 0.049 | 0.05 | Epithelial sodium channel blocker | |||
| 0.134 | 0.133 | 0.36 | DNA methylase inhibitor | 0.36 0.015 DBMET02368 | DBMET02368 | |
| 0.048 | 0.048 | 0.077 | 5 Hydroxytryptamine 1B agonist | 0.077 0.013 DBMET02368 | DBMET02368 | |
| 0.031 | 0.034 | 0.039 | Bombesin 1 receptor antagonist | 0.039 0.023 DBMET02368 | DBMET02368 | |
| 0.042 | 0.045 | 0.045 | Bombesin antagonist | 0.045 0.038 DBMET02368 | DBMET02368 | |
| 0.08 | 0.086 | 0.132 | Protein kinase C zeta inhibitor | 0.132 0.026 DBMET02368 | DBMET02368 | |
| 0.028 | 0.039 | 0.044 | Somatostatin 1 antagonist | 0.044 0.023 DBMET02368 | DBMET02368 | |
| 0.086 | 0.101 | 0.093 | Folate antagonist | 0.093 0.081 DBMET02368 | DBMET02368 | |
| 0.031 | 0.046 | 0.037 | Growth hormone release inhibitor | 0.037 0.036 DBMET02368 | DBMET02368 | |
| 0.181 | 0.199 | 0.467 | Vasodilator, peripheral | 0.467 0.036 DBMET02368 | DBMET02368 | |
| 0.142 | 0.162 | 0.168 | Immunostimulant | 0.168 0.141 DBMET02368 | DBMET02368 | |
| 0.057 | 0.076 | 0.074 | Calcium channel P-type blocker | 0.074 0.022 DBMET02368 | DBMET02368 | |
| 0.023 | 0.044 | 0.041 | Melatonin 2 agonist | 0.041 0.015 DBMET02368 | DBMET02368 | |
| 0.232 | 0.255 | 0.575 | 5 Hydroxytryptamine release inhibitor | 0.575 0.015 DBMET02368 | DBMET02368 | |
| 0.026 | 0.053 | 0.037 | Cholecystokinin B agonist | 0.037 0.027 DBMET02368 | DBMET02368 | |
| 0.007 | 0.037 | 0.011 | Melatonin 2 antagonist | 0.011 0.01 DBMET02368 | DBMET02368 | |
| 0.086 | 0.119 | 0.234 | Tubulin antagonist | 0.234 0.028 DBMET02368 | DBMET02368 | |
| 0.065 | 0.103 | 0.103 | Protein kinase C delta inhibitor | 0.103 0.05 DBMET02368 | DBMET02368 | |
| 0.185 | 0.228 | 0.485 | GABA C receptor rho-3 antagonist | 0.485 0.03 DBMET02368 | DBMET02368 | |
| 0.014 | 0.059 | 0.024 | Follicle-stimulating hormone antagonist | 0.024 0.007 DBMET02368 | DBMET02368 | |
| 0.008 | 0.054 | 0.018 | Cholecystokinin agonist | 0.018 0.013 DBMET02368 | DBMET02368 | |
| 0.039 | 0.085 | 0.056 | Factor III inhibitor | 0.056 0.023 DBMET02368 | DBMET02368 | |
| 0.057 | 0.104 | 0.139 | Histamine N-methyltransferase inhibitor | 0.139 0.018 DBMET02368 | DBMET02368 | |
| 0.107 | 0.157 | 0.316 | GABA C receptor rho-2 antagonist | 0.316 0.005 DBMET02368 | DBMET02368 | |
| 0.127 | 0.178 | 0.248 | Antiamyloidogenic | 0.248 0.072 DBMET02368 | DBMET02368 | |
| 0.173 | 0.225 | 0.323 | Apoptosis antagonist | 0.323 0.07 DBMET02368 | DBMET02368 | |
| 0.009 | 0.062 | 0.056 | Somatostatin 5 antagonist | 0.056 0.011 DBMET02368 | DBMET02368 | |
| 0.007 | 0.063 | 0.018 | Cholecystokinin A agonist | 0.018 0.01 DBMET02368 | DBMET02368 | |
| 0.059 | 0.117 | 0.24 | GABA B receptor agonist | 0.24 0.003 DBMET02368 | DBMET02368 | |
| 0.062 | 0.12 | 0.171 | Prolactin inhibitor | 0.171 0.015 DBMET02368 | DBMET02368 | |
| 0.065 | 0.136 | 0.128 | D-Ala-D-Ala ligase inhibitor | 0.128 0.01 DBMET02368 | DBMET02368 | |
| 0.033 | 0.108 | 0.053 | Glucose-6-phosphate translocase inhibitor | 0.053 0.033 DBMET02368 | DBMET02368 | |
| 0.108 | 0.191 | 0.146 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.146 0.115 DBMET02368 | DBMET02368 | |
| 0.044 | 0.128 | 0.08 | Acetylcholine nicotinic antagonist | 0.08 0.054 DBMET02368 | DBMET02368 | |
| 0.081 | 0.168 | 0.518 | Peroxidase inhibitor | 0.518 0.008 DBMET02368 | DBMET02368 | |
| 0.049 | 0.138 | 0.063 | Prolactin release inhibitor | 0.063 0.041 DBMET02368 | DBMET02368 | |
| 0.194 | 0.284 | 0.529 | Calcium channel L-type activator | 0.529 0.018 DBMET02368 | DBMET02368 | |
| 0.063 | 0.157 | 0.079 | Estrogen-related receptor beta agonist | 0.079 0.071 DBMET02368 | DBMET02368 | |
| 0.008 | 0.102 | 0.041 | Cholecystokinin A antagonist | 0.041 0.023 DBMET02368 | DBMET02368 | |
| 0.045 | 0.141 | 0.14 | Monophenol monooxygenase inhibitor | 0.14 0.051 DBMET02368 | DBMET02368 | |
| 0.086 | 0.184 | 0.191 | Psychostimulant | 0.191 0.085 DBMET02368 | DBMET02368 | |
| 0.055 | 0.156 | 0.12 | Topoisomerase II inhibitor | 0.12 0.067 DBMET02368 | DBMET02368 | |
| 0.006 | 0.109 | 0.02 | Follicle-stimulating hormone agonist | 0.02 0.018 DBMET02368 | DBMET02368 | |
| 0.009 | 0.113 | 0.021 | Bombesin agonist | 0.021 0.019 DBMET02368 | DBMET02368 | |
| 0.07 | 0.175 | 0.125 | Alkaline phosphatase inhibitor | 0.125 0.081 DBMET02368 | DBMET02368 | |
| 0.033 | 0.141 | 0.081 | 5 Hydroxytryptamine 7 agonist | 0.081 0.012 DBMET02368 | DBMET02368 | |
| 0.059 | 0.167 | 0.124 | Adenylate cyclase inhibitor | 0.124 0.064 DBMET02368 | DBMET02368 | |
| 0.07 | 0.18 | 0.097 | CDC-like kinase 3 inhibitor | 0.097 0.086 DBMET02368 | DBMET02368 | |
| 0.091 | 0.203 | 0.13 | Nitric oxide antagonist | 0.13 0.119 DBMET02368 | DBMET02368 | |
| 0.041 | 0.153 | 0.098 | Ryanodine receptor antagonist | 0.098 0.004 DBMET02368 | DBMET02368 | |
| 0.108 | 0.226 | 0.154 | Phospholipase C inhibitor | 0.154 0.099 DBMET02368 | DBMET02368 | |
| 0.022 | 0.141 | 0.07 | Argininosuccinate synthase inhibitor | 0.07 0.03 DBMET02368 | DBMET02368 | |
| 0.105 | 0.225 | 0.153 | ATPase inhibitor | 0.153 0.097 DBMET02368 | DBMET02368 | |
| 0.043 | 0.167 | 0.098 | Aminopeptidase B inhibitor | 0.098 0.067 DBMET02368 | DBMET02368 | |
| 0.071 | 0.196 | 0.133 | Interleukin 4 antagonist | 0.133 0.067 DBMET02368 | DBMET02368 | |
| 0.008 | 0.134 | 0.05 | Cholecystokinin antagonist | 0.05 0.025 DBMET02368 | DBMET02368 | |
| 0.089 | 0.218 | 0.154 | Adenylate cyclase stimulant | 0.154 0.056 DBMET02368 | DBMET02368 | |
| 0.111 | 0.243 | 0.149 | Cyclin-dependent kinase 3 inhibitor | 0.149 0.097 DBMET02368 | DBMET02368 | |
| 0.113 | 0.246 | 0.177 | Heat shock protein 70 antagonist | 0.177 0.013 DBMET02368 | DBMET02368 | |
| 0.054 | 0.188 | 0.244 | GABA C receptor rho-1 antagonist | 0.244 0.005 DBMET02368 | DBMET02368 | |
| 0.132 | 0.267 | 0.207 | Angiogenesis inhibitor | 0.207 0.162 DBMET02368 | DBMET02368 | |
| 0.066 | 0.202 | 0.239 | NADPH oxidase inhibitor | 0.239 0.023 DBMET02368 | DBMET02368 | |
| 0.051 | 0.189 | 0.094 | EphA2 antagonist | 0.094 0.083 DBMET02368 | DBMET02368 | |
| 0.037 | 0.175 | 0.092 | Beta 3 adrenoreceptor antagonist | 0.092 0.017 DBMET02368 | DBMET02368 | |
| 0.138 | 0.282 | 0.242 | 5 Hydroxytryptamine 3E antagonist | 0.242 0.02 DBMET02368 | DBMET02368 | |
| 0.083 | 0.231 | 0.228 | Antimitotic | 0.228 0.069 DBMET02368 | DBMET02368 | |
| 0.025 | 0.173 | 0.087 | Cyclin D1 inhibitor | 0.087 0.013 DBMET02368 | DBMET02368 | |
| 0.024 | 0.173 | 0.077 | Neuronal nicotinic receptor antagonist | 0.077 0.039 DBMET02368 | DBMET02368 | |
| 0.026 | 0.175 | 0.256 | Histidine decarboxylase inhibitor | 0.256 0.009 DBMET02368 | DBMET02368 | |
| 0.073 | 0.223 | 0.221 | Phospholipase A2 inhibitor | 0.221 0.033 DBMET02368 | DBMET02368 | |
| 0.018 | 0.17 | 0.067 | Plasminogen activator inhibitor antagonist | 0.067 0.02 DBMET02368 | DBMET02368 | |
| 0.03 | 0.196 | 0.064 | Potassium channel (ATP-sensitive) blocker | 0.064 0.052 DBMET02368 | DBMET02368 | |
| 0.021 | 0.191 | 0.079 | Protein kinase C eta inhibitor | 0.079 0.024 DBMET02368 | DBMET02368 | |
| 0.131 | 0.306 | 0.316 | Sodium/bile acid cotransporter inhibitor | 0.316 0.065 DBMET02368 | DBMET02368 | |
| 0.043 | 0.221 | 0.138 | Breast cancer-resistant protein inhibitor | 0.138 0.029 DBMET02368 | DBMET02368 | |
| 0.057 | 0.245 | 0.107 | Glutamate release inhibitor | 0.107 0.034 DBMET02368 | DBMET02368 | |
| 0.1 | 0.294 | 0.164 | Catenin beta inhibitor | 0.164 0.076 DBMET02368 | DBMET02368 | |
| 0.044 | 0.24 | 0.202 | Xanthine oxidase inhibitor | 0.202 0.019 DBMET02368 | DBMET02368 | |
| 0.039 | 0.237 | 0.114 | Antineoplastic alkaloid | 0.114 0.04 DBMET02368 | DBMET02368 | |
| 0.056 | 0.255 | 0.12 | Neurotrophic factor | 0.12 0.095 DBMET02368 | DBMET02368 | |
| 0.043 | 0.245 | 0.137 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.137 0.087 DBMET02368 | DBMET02368 | |
| 0.074 | 0.276 | 0.631 | Aldehyde oxidase inhibitor | 0.631 0.015 DBMET02368 | DBMET02368 | |
| 0.015 | 0.22 | 0.043 | Dihydrofolate reductase inhibitor | 0.043 0.031 DBMET02368 | DBMET02368 | |
| 0.035 | 0.241 | 0.14 | Mediator release inhibitor | 0.14 0.033 DBMET02368 | DBMET02368 | |
| 0.043 | 0.251 | 0.264 | AMP-activated protein kinase stimulant | 0.264 0.006 DBMET02368 | DBMET02368 | |
| 0.114 | 0.324 | 0.282 | Vasodilator, coronary | 0.282 0.103 DBMET02368 | DBMET02368 | |
| 0.037 | 0.249 | 0.115 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.115 0.028 DBMET02368 | DBMET02368 | |
| 0.008 | 0.22 | 0.044 | Dihydropteroate synthase inhibitor | 0.044 0.022 DBMET02368 | DBMET02368 | |
| 0.091 | 0.303 | 0.292 | Cyclic AMP phosphodiesterase inhibitor | 0.292 0.045 DBMET02368 | DBMET02368 | |
| 0.022 | 0.236 | 0.074 | CDC25B inhibitor | 0.074 0.033 DBMET02368 | DBMET02368 | |
| 0.103 | 0.324 | 0.32 | Alpha-glucosidase inhibitor | 0.32 0.15 DBMET02368 | DBMET02368 | |
| 0.049 | 0.272 | 0.194 | Carbonic anhydrase XV inhibitor | 0.194 0.019 DBMET02368 | DBMET02368 | |
| 0.045 | 0.272 | 0.145 | Granulocyte macrophage colony stimulating factor agonist | 0.145 0.006 DBMET02368 | DBMET02368 | |
| 0.1 | 0.328 | 0.24 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.24 0.047 DBMET02368 | DBMET02368 | |
| 0.017 | 0.246 | 0.062 | Beta 1 adrenoreceptor antagonist | 0.062 0.034 DBMET02368 | DBMET02368 | |
| 0.038 | 0.272 | 0.096 | Alpha 2b adrenoreceptor antagonist | 0.096 0.078 DBMET02368 | DBMET02368 | |
| 0.008 | 0.246 | 0.039 | NMDA 2D receptor antagonist | 0.039 0.01 DBMET02368 | DBMET02368 | |
| 0.096 | 0.335 | 0.281 | Gastrin inhibitor | 0.281 0.048 DBMET02368 | DBMET02368 | |
| 0.004 | 0.242 | 0.02 | Endothelin B receptor antagonist | 0.02 0.013 DBMET02368 | DBMET02368 | |
| 0.088 | 0.331 | 0.211 | 12-Lipoxygenase inhibitor | 0.211 0.139 DBMET02368 | DBMET02368 | |
| 0.085 | 0.329 | 0.164 | MAP kinase kinase 4 inhibitor | 0.164 0.04 DBMET02368 | DBMET02368 | |
| 0.131 | 0.374 | 0.306 | 5 Hydroxytryptamine uptake stimulant | 0.306 0.042 DBMET02368 | DBMET02368 | |
| 0.122 | 0.37 | 0.447 | Calcium channel activator | 0.447 0.012 DBMET02368 | DBMET02368 | |
| 0.093 | 0.343 | 0.332 | DNA synthesis inhibitor | 0.332 0.034 DBMET02368 | DBMET02368 | |
| 0.073 | 0.324 | 0.244 | CF transmembrane conductance regulator agonist | 0.244 0.007 DBMET02368 | DBMET02368 | |
| 0.026 | 0.277 | 0.126 | Alcohol dehydrogenase inhibitor | 0.126 0.031 DBMET02368 | DBMET02368 | |
| 0.178 | 0.43 | 0.568 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.568 0.012 DBMET02368 | DBMET02368 | |
| 0.04 | 0.291 | 0.194 | Amylase inhibitor | 0.194 0.046 DBMET02368 | DBMET02368 | |
| 0.056 | 0.308 | 0.214 | Insulin sensitizer | 0.214 0.06 DBMET02368 | DBMET02368 | |
| 0.026 | 0.278 | 0.097 | Glycine receptor antagonist | 0.097 0.035 DBMET02368 | DBMET02368 | |
| 0.05 | 0.305 | 0.13 | LIM domain kinase 1 inhibitor | 0.13 0.121 DBMET02368 | DBMET02368 | |
| 0.005 | 0.26 | 0.024 | Beta 1 adrenoreceptor agonist | 0.024 0.014 DBMET02368 | DBMET02368 | |
| 0.051 | 0.307 | 0.202 | Adenylate kinase inhibitor | 0.202 0.015 DBMET02368 | DBMET02368 | |
| 0.025 | 0.281 | 0.053 | CD45 antagonist | 0.053 0.03 DBMET02368 | DBMET02368 | |
| 0.06 | 0.318 | 0.249 | Interleukin agonist | 0.249 0.08 DBMET02368 | DBMET02368 | |
| 0.021 | 0.279 | 0.091 | Platelet growth factor antagonist | 0.091 0.047 DBMET02368 | DBMET02368 | |
| 0.024 | 0.284 | 0.071 | GABA aminotransferase inhibitor | 0.071 0.059 DBMET02368 | DBMET02368 | |
| 0.034 | 0.294 | 0.186 | GABA C receptor antagonist | 0.186 0.016 DBMET02368 | DBMET02368 | |
| 0.025 | 0.293 | 0.143 | Macrophage migration inhibitory factor inhibitor | 0.143 0.017 DBMET02368 | DBMET02368 | |
| 0.024 | 0.295 | 0.09 | Topoisomerase I inhibitor | 0.09 0.079 DBMET02368 | DBMET02368 | |
| 0.049 | 0.323 | 0.141 | Cell wall synthesis inhibitor | 0.141 0.074 DBMET02368 | DBMET02368 | |
| 0.016 | 0.29 | 0.047 | Beta 2 adrenoreceptor antagonist | 0.047 0.041 DBMET02368 | DBMET02368 | |
| 0.004 | 0.279 | 0.019 | Endothelin A receptor antagonist | 0.019 0.018 DBMET02368 | DBMET02368 | |
| 0.004 | 0.28 | 0.031 | Endothelin receptor antagonist | 0.031 0.017 DBMET02368 | DBMET02368 | |
| 0.011 | 0.292 | 0.069 | Nicotinic receptor alpha7 subunit antagonist | 0.069 0.022 DBMET02368 | DBMET02368 | |
| 0.028 | 0.31 | 0.113 | Gastric antisecretory | 0.113 0.05 DBMET02368 | DBMET02368 | |
| 0.023 | 0.306 | 0.092 | Adrenaline agonist | 0.092 0.044 DBMET02368 | DBMET02368 | |
| 0.02 | 0.306 | 0.07 | Beta adrenoreceptor antagonist | 0.07 0.038 DBMET02368 | DBMET02368 | |
| 0.033 | 0.321 | 0.158 | CDC-like kinase 1 inhibitor | 0.158 0.064 DBMET02368 | DBMET02368 | |
| 0.111 | 0.401 | 0.274 | Tyrosine 3 hydroxylase inhibitor | 0.274 0.049 DBMET02368 | DBMET02368 | |
| 0.01 | 0.307 | 0.142 | Xanthine dehydrogenase inhibitor | 0.142 0.008 DBMET02368 | DBMET02368 | |
| 0.004 | 0.301 | 0.044 | Uridine phosphorylase inhibitor | 0.044 0.01 DBMET02368 | DBMET02368 | |
| 0.015 | 0.313 | 0.067 | GABA B receptor antagonist | 0.067 0.009 DBMET02368 | DBMET02368 | |
| 0.038 | 0.338 | 0.168 | Mcl-1 antagonist | 0.168 0.075 DBMET02368 | DBMET02368 | |
| 0.012 | 0.314 | 0.053 | Lysophosphatidic acid 3 receptor antagonist | 0.053 0.03 DBMET02368 | DBMET02368 | |
| 0.036 | 0.34 | 0.102 | Beta amyloid protein antagonist | 0.102 0.087 DBMET02368 | DBMET02368 | |
| 0.011 | 0.319 | 0.058 | HIV-1 integrase (3'-Processing) inhibitor | 0.058 0.05 DBMET02368 | DBMET02368 | |
| 0.061 | 0.372 | 0.265 | Succinate dehydrogenase inhibitor | 0.265 0.018 DBMET02368 | DBMET02368 | |
| 0.044 | 0.357 | 0.16 | TRPA1 agonist | 0.16 0.025 DBMET02368 | DBMET02368 | |
| 0.007 | 0.32 | 0.03 | Thyroid hormone agonist | 0.03 0.012 DBMET02368 | DBMET02368 | |
| 0.059 | 0.372 | 0.155 | Non-steroidal antiinflammatory agent | 0.155 0.109 DBMET02368 | DBMET02368 | |
| 0.067 | 0.381 | 0.191 | Focal adhesion kinase 2 inhibitor | 0.191 0.077 DBMET02368 | DBMET02368 | |
| 0.042 | 0.357 | 0.159 | Photosensitizer | 0.159 0.026 DBMET02368 | DBMET02368 | |
| 0.041 | 0.357 | 0.18 | Aldehyde dehydrogenase inhibitor | 0.18 0.033 DBMET02368 | DBMET02368 | |
| 0.103 | 0.42 | 0.275 | Nitric-oxide synthase stimulant | 0.275 0.019 DBMET02368 | DBMET02368 | |
| 0.035 | 0.357 | 0.219 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.219 0.082 DBMET02368 | DBMET02368 | |
| 0.026 | 0.355 | 0.126 | Carbonic anhydrase VI inhibitor | 0.126 0.027 DBMET02368 | DBMET02368 | |
| 0.007 | 0.337 | 0.041 | NMDA receptor subunit 3B antagonist | 0.041 0.034 DBMET02368 | DBMET02368 | |
| 0.015 | 0.353 | 0.057 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.057 0.009 DBMET02368 | DBMET02368 | |
| 0.092 | 0.431 | 0.166 | Ca2+-transporting ATPase inhibitor | 0.166 0.016 DBMET02368 | DBMET02368 | |
| 0.041 | 0.38 | 0.116 | Interleukin 1 antagonist | 0.116 0.094 DBMET02368 | DBMET02368 | |
| 0.055 | 0.396 | 0.146 | Hepatoprotectant | 0.146 0.114 DBMET02368 | DBMET02368 | |
| 0.032 | 0.375 | 0.217 | Dyrk kinase inhibitor | 0.217 0.089 DBMET02368 | DBMET02368 | |
| 0.071 | 0.415 | 0.185 | Histone acetyltransferase inhibitor | 0.185 0.093 DBMET02368 | DBMET02368 | |
| 0.005 | 0.352 | 0.053 | Beta tubulin antagonist | 0.053 0.044 DBMET02368 | DBMET02368 | |
| 0.099 | 0.447 | 0.161 | ErbB-1 antagonist | 0.161 0.153 DBMET02368 | DBMET02368 | |
| 0.009 | 0.359 | 0.053 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.053 0.048 DBMET02368 | DBMET02368 | |
| 0.028 | 0.383 | 0.194 | HIV-1 integrase (Overall Integration) inhibitor | 0.194 0.013 DBMET02368 | DBMET02368 | |
| 0.035 | 0.391 | 0.137 | Protein kinase stimulant | 0.137 0.078 DBMET02368 | DBMET02368 | |
| 0.071 | 0.428 | 0.376 | 15-Lipoxygenase inhibitor | 0.376 0.085 DBMET02368 | DBMET02368 | |
| 0.037 | 0.401 | 0.117 | Interleukin 8 antagonist | 0.117 0.066 DBMET02368 | DBMET02368 | |
| 0.029 | 0.394 | 0.159 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.159 0.111 DBMET02368 | DBMET02368 | |
| 0.021 | 0.389 | 0.129 | Mucolytic | 0.129 0.046 DBMET02368 | DBMET02368 | |
| 0.038 | 0.413 | 0.204 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.204 0.098 DBMET02368 | DBMET02368 | |
| 0.017 | 0.395 | 0.106 | Glycogen synthase kinase-3 alpha inhibitor | 0.106 0.097 DBMET02368 | DBMET02368 | |
| 0.013 | 0.399 | 0.075 | Protein kinase C beta inhibitor | 0.075 0.038 DBMET02368 | DBMET02368 | |
| 0.012 | 0.398 | 0.088 | Glutamate decarboxylase inhibitor | 0.088 0.037 DBMET02368 | DBMET02368 | |
| 0.035 | 0.423 | 0.166 | Arachidonic acid antagonist | 0.166 0.07 DBMET02368 | DBMET02368 | |
| 0.054 | 0.443 | 0.19 | Interferon gamma antagonist | 0.19 0.045 DBMET02368 | DBMET02368 | |
| 0.051 | 0.442 | 0.253 | Lipoxygenase inhibitor | 0.253 0.098 DBMET02368 | DBMET02368 | |
| 0.009 | 0.402 | 0.05 | Leukotriene B4 antagonist | 0.05 0.043 DBMET02368 | DBMET02368 | |
| 0.025 | 0.424 | 0.136 | Cytidine deaminase inhibitor | 0.136 0.086 DBMET02368 | DBMET02368 | |
| 0.049 | 0.448 | 0.297 | 3C-like protease (Human coronavirus) inhibitor | 0.297 0.012 DBMET02368 | DBMET02368 | |
| 0.01 | 0.417 | 0.151 | Catalase inhibitor | 0.151 0.026 DBMET02368 | DBMET02368 | |
| 0.014 | 0.424 | 0.059 | Carnitine palmitoyltransferase 1B inhibitor | 0.059 0.018 DBMET02368 | DBMET02368 | |
| 0.026 | 0.437 | 0.057 | Immunoglobulin Fc receptor antagonist | 0.057 0.031 DBMET02368 | DBMET02368 | |
| 0.014 | 0.427 | 0.112 | Expectorant | 0.112 0.057 DBMET02368 | DBMET02368 | |
| 0.023 | 0.441 | 0.118 | Uric acid excretion stimulant | 0.118 0.039 DBMET02368 | DBMET02368 | |
| 0.021 | 0.443 | 0.157 | Protein-tyrosine phosphatase inhibitor | 0.157 0.071 DBMET02368 | DBMET02368 | |
| 0.007 | 0.432 | 0.053 | GABA A receptor antagonist | 0.053 0.037 DBMET02368 | DBMET02368 | |
| 0.052 | 0.478 | 0.34 | Transcription factor NF kappa B inhibitor | 0.34 0.08 DBMET02368 | DBMET02368 | |
| 0.026 | 0.452 | 0.25 | I kappa B kinase epsilon inhibitor | 0.25 0.037 DBMET02368 | DBMET02368 | |
| 0.013 | 0.442 | 0.122 | M17 leucyl aminopeptidase inhibitor | 0.122 0.076 DBMET02368 | DBMET02368 | |
| 0.013 | 0.444 | 0.045 | Beta adrenoreceptor agonist | 0.045 0.032 DBMET02368 | DBMET02368 | |
| 0.022 | 0.456 | 0.2 | Keratolytic | 0.2 0.008 DBMET02368 | DBMET02368 | |
| 0.027 | 0.464 | 0.184 | Carbonic anhydrase III inhibitor | 0.184 0.019 DBMET02368 | DBMET02368 | |
| 0.063 | 0.502 | 0.541 | Histamine release inhibitor | 0.541 0.018 DBMET02368 | DBMET02368 | |
| 0.006 | 0.445 | 0.056 | GABA receptor antagonist | 0.056 0.036 DBMET02368 | DBMET02368 | |
| 0.002 | 0.445 | 0.019 | Inosine monophosphate dehydrogenase 2 inhibitor | 0.019 0.014 DBMET02368 | DBMET02368 | |
| 0.035 | 0.478 | 0.152 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.152 0.125 DBMET02368 | DBMET02368 | |
| 0.02 | 0.465 | 0.121 | GABA receptor agonist | 0.121 0.055 DBMET02368 | DBMET02368 | |
| 0.032 | 0.484 | 0.169 | Cyclooxygenase 3 inhibitor | 0.169 0.034 DBMET02368 | DBMET02368 | |
| 0.028 | 0.483 | 0.199 | DOPA decarboxylase inhibitor | 0.199 0.007 DBMET02368 | DBMET02368 | |
| 0.044 | 0.51 | 0.198 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.198 0.019 DBMET02368 | DBMET02368 | |
| 0.003 | 0.468 | 0.05 | Free fatty acid receptor 1 antagonist | 0.05 0.009 DBMET02368 | DBMET02368 | |
| 0.031 | 0.497 | 0.095 | Phosphodiesterase 6D inhibitor | 0.095 0.063 DBMET02368 | DBMET02368 | |
| 0.008 | 0.479 | 0.118 | Protein-tyrosine phosphatase 1B inhibitor | 0.118 0.065 DBMET02368 | DBMET02368 | |
| 0.006 | 0.478 | 0.143 | Alcohol oxidase inhibitor | 0.143 0.011 DBMET02368 | DBMET02368 | |
| 0.016 | 0.493 | 0.213 | Cystathionine beta-synthase inhibitor | 0.213 0.022 DBMET02368 | DBMET02368 | |
| 0.023 | 0.501 | 0.113 | Bile acid receptor antagonist | 0.113 0.027 DBMET02368 | DBMET02368 | |
| 0.008 | 0.486 | 0.044 | Mineralocorticoid receptor antagonist | 0.044 0.039 DBMET02368 | DBMET02368 | |
| 0.011 | 0.491 | 0.069 | Aryl hydrocarbon receptor antagonist | 0.069 0.039 DBMET02368 | DBMET02368 | |
| 0.005 | 0.486 | 0.065 | Leukotriene antagonist | 0.065 0.045 DBMET02368 | DBMET02368 | |
| 0.009 | 0.494 | 0.034 | Protein kinase C beta I inhibitor | 0.034 0.021 DBMET02368 | DBMET02368 | |
| 0.014 | 0.5 | 0.095 | Carbonic anhydrase XIII inhibitor | 0.095 0.041 DBMET02368 | DBMET02368 | |
| 0.003 | 0.491 | 0.033 | Kainate receptor 2 antagonist | 0.033 0.027 DBMET02368 | DBMET02368 | |
| 0.024 | 0.53 | 0.109 | Acetylcholine release stimulant | 0.109 0.068 DBMET02368 | DBMET02368 | |
| 0.044 | 0.561 | 0.135 | Sphingosine 1-phosphate receptor 5 antagonist | 0.135 0.09 DBMET02368 | DBMET02368 | |
| 0.012 | 0.531 | 0.094 | Glutamate (mGluR7) antagonist | 0.094 0.014 DBMET02368 | DBMET02368 | |
| 0.015 | 0.536 | 0.05 | Nicotinic alpha3beta2 receptor antagonist | 0.05 0.044 DBMET02368 | DBMET02368 | |
| 0.015 | 0.541 | 0.126 | Creatine kinase inhibitor | 0.126 0.037 DBMET02368 | DBMET02368 | |
| 0.005 | 0.536 | 0.043 | Nicotinic acid receptor 2 agonist | 0.043 0.018 DBMET02368 | DBMET02368 | |
| 0.004 | 0.537 | 0.033 | Inosine monophosphate dehydrogenase inhibitor | 0.033 0.029 DBMET02368 | DBMET02368 | |
| 0.013 | 0.547 | 0.083 | Polo-like kinase-1 inhibitor | 0.083 0.077 DBMET02368 | DBMET02368 | |
| 0.011 | 0.546 | 0.075 | GABA A receptor agonist | 0.075 0.073 DBMET02368 | DBMET02368 | |
| 0.012 | 0.549 | 0.059 | Heparanase inhibitor | 0.059 0.025 DBMET02368 | DBMET02368 | |
| 0.003 | 0.541 | 0.055 | Carnitine palmitoyltransferase inhibitor | 0.055 0.006 DBMET02368 | DBMET02368 | |
| 0.003 | 0.543 | 0.054 | Carnitine palmitoyltransferase 1 inhibitor | 0.054 0.006 DBMET02368 | DBMET02368 | |
| 0.02 | 0.563 | 0.196 | Triose-phosphate isomerase inhibitor | 0.196 0.011 DBMET02368 | DBMET02368 | |
| 0.014 | 0.56 | 0.293 | GABA C receptor agonist | 0.293 0.01 DBMET02368 | DBMET02368 | |
| 0.02 | 0.569 | 0.068 | Adenine nucleotide translocase inhibitor | 0.068 0.017 DBMET02368 | DBMET02368 | |
| 0.003 | 0.552 | 0.038 | Kainate receptor antagonist | 0.038 0.031 DBMET02368 | DBMET02368 | |
| 0.004 | 0.554 | 0.029 | Carnitine palmitoyltransferase 1A inhibitor | 0.029 0.019 DBMET02368 | DBMET02368 | |
| 0.021 | 0.574 | 0.09 | MAP kinase kinase 7 inhibitor | 0.09 0.024 DBMET02368 | DBMET02368 | |
| 0.007 | 0.56 | 0.115 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.115 0.031 DBMET02368 | DBMET02368 | |
| 0.011 | 0.567 | 0.064 | Pregnane X receptor antagonist | 0.064 0.022 DBMET02368 | DBMET02368 | |
| 0.007 | 0.566 | 0.153 | Porphobilinogen synthase inhibitor | 0.153 0.02 DBMET02368 | DBMET02368 | |
| 0.023 | 0.582 | 0.109 | Sphingosine 1-phosphate receptor 4 antagonist | 0.109 0.097 DBMET02368 | DBMET02368 | |
| 0.009 | 0.569 | 0.054 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.054 0.037 DBMET02368 | DBMET02368 | |
| 0.024 | 0.589 | 0.101 | Interleukin 1b antagonist | 0.101 0.079 DBMET02368 | DBMET02368 | |
| 0.014 | 0.579 | 0.059 | Topoisomerase II beta inhibitor | 0.059 0.023 DBMET02368 | DBMET02368 | |
| 0.004 | 0.576 | 0.072 | Prostaglandin EP2 antagonist | 0.072 0.031 DBMET02368 | DBMET02368 | |
| 0.007 | 0.581 | 0.139 | Phenylalanine 4-hydroxylase inhibitor | 0.139 0.014 DBMET02368 | DBMET02368 | |
| 0.011 | 0.586 | 0.104 | Cholesterol synthesis inhibitor | 0.104 0.082 DBMET02368 | DBMET02368 | |
| 0.004 | 0.588 | 0.065 | Phosphofructokinase-1 inhibitor | 0.065 0.052 DBMET02368 | DBMET02368 | |
| 0.003 | 0.587 | 0.042 | Peroxisome proliferator-activated receptor alpha agonist | 0.042 0.04 DBMET02368 | DBMET02368 | |
| 0.002 | 0.592 | 0.04 | Fructose-1,6-bisphosphatase inhibitor | 0.04 0.039 DBMET02368 | DBMET02368 | |
| 0.027 | 0.618 | 0.182 | Transcription factor STAT3 inhibitor | 0.182 0.161 DBMET02368 | DBMET02368 | |
| 0.032 | 0.625 | 0.155 | Neurotrophic factor enhancer | 0.155 0.131 DBMET02368 | DBMET02368 | |
| 0.002 | 0.6 | 0.018 | Retinoic acid alpha receptor antagonist | 0.018 0.017 DBMET02368 | DBMET02368 | |
| 0.026 | 0.644 | 0.269 | Hypoxia-inducible factor 1 alpha inhibitor | 0.269 0.084 DBMET02368 | DBMET02368 | |
| 0.002 | 0.621 | 0.025 | Nicotinic acid receptor 2 antagonist | 0.025 0.021 DBMET02368 | DBMET02368 | |
| 0.008 | 0.632 | 0.043 | Kainate receptor agonist | 0.043 0.026 DBMET02368 | DBMET02368 | |
| 0.014 | 0.637 | 0.14 | Mannose-6-phosphate isomerase inhibitor | 0.14 0.074 DBMET02368 | DBMET02368 | |
| 0.004 | 0.628 | 0.063 | Dihydroorotate dehydrogenase inhibitor | 0.063 0.026 DBMET02368 | DBMET02368 | |
| 0.005 | 0.633 | 0.034 | Purinergic P2Y14 antagonist | 0.034 0.016 DBMET02368 | DBMET02368 | |
| 0.028 | 0.672 | 0.219 | Tumour necrosis factor antagonist | 0.219 0.043 DBMET02368 | DBMET02368 | |
| 0.028 | 0.674 | 0.33 | Cholesterol antagonist | 0.33 0.074 DBMET02368 | DBMET02368 | |
| 0.013 | 0.661 | 0.077 | Glycine receptor agonist | 0.077 0.042 DBMET02368 | DBMET02368 | |
| 0.006 | 0.656 | 0.082 | Aconitate hydratase inhibitor | 0.082 0.013 DBMET02368 | DBMET02368 | |
| 0.018 | 0.671 | 0.141 | NADH dehydrogenase inhibitor | 0.141 0.02 DBMET02368 | DBMET02368 | |
| 0.003 | 0.656 | 0.073 | NMDA receptor glycine site agonist | 0.073 0.033 DBMET02368 | DBMET02368 | |
| 0.01 | 0.663 | 0.113 | Microtubule formation inhibitor | 0.113 0.069 DBMET02368 | DBMET02368 | |
| 0.005 | 0.66 | 0.036 | Integrin alpha2 antagonist | 0.036 0.028 DBMET02368 | DBMET02368 | |
| 0.007 | 0.663 | 0.063 | NMDA receptor agonist | 0.063 0.044 DBMET02368 | DBMET02368 | |
| 0.01 | 0.667 | 0.191 | MAP kinase kinase 2 inhibitor | 0.191 0.088 DBMET02368 | DBMET02368 | |
| 0.009 | 0.692 | 0.144 | Ferrochelatase inhibitor | 0.144 0.04 DBMET02368 | DBMET02368 | |
| 0.006 | 0.691 | 0.082 | Peroxisome proliferator-activated receptor gamma antagonist | 0.082 0.031 DBMET02368 | DBMET02368 | |
| 0.009 | 0.695 | 0.048 | Aldosterone antagonist | 0.048 0.032 DBMET02368 | DBMET02368 | |
| 0.014 | 0.704 | 0.101 | Electrolyte absorption antagonist | 0.101 0.057 DBMET02368 | DBMET02368 | |
| 0.003 | 0.703 | 0.119 | Protein kinase (CK2) alpha inhibitor | 0.119 0.063 DBMET02368 | DBMET02368 | |
| 0.011 | 0.714 | 0.102 | Potassium channel (Ca-activated) activator | 0.102 0.054 DBMET02368 | DBMET02368 | |
| 0.026 | 0.731 | 0.244 | RNA-directed DNA polymerase inhibitor | 0.244 0.053 DBMET02368 | DBMET02368 | |
| 0.004 | 0.71 | 0.059 | Dihydroorotase inhibitor | 0.059 0.017 DBMET02368 | DBMET02368 | |
| 0.014 | 0.728 | 0.192 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.192 0.017 DBMET02368 | DBMET02368 | |
| 0.011 | 0.727 | 0.068 | MDM2 inhibitor | 0.068 0.045 DBMET02368 | DBMET02368 | |
| 0.011 | 0.738 | 0.074 | Glutamate dehydrogenase inhibitor | 0.074 0.051 DBMET02368 | DBMET02368 | |
| 0.006 | 0.737 | 0.041 | Glutamate (mGluR8) agonist | 0.041 0.02 DBMET02368 | DBMET02368 | |
| 0.026 | 0.756 | 0.268 | Cyclophilin D inhibitor | 0.268 0.192 DBMET02368 | DBMET02368 | |
| 0.003 | 0.741 | 0.03 | Glutamate (mGluR3) agonist | 0.03 0.029 DBMET02368 | DBMET02368 | |
| 0.003 | 0.741 | 0.039 | Nicotinic acid receptor agonist | 0.039 0.022 DBMET02368 | DBMET02368 | |
| 0.01 | 0.757 | 0.066 | Purinergic P2X1 antagonist | 0.066 0.036 DBMET02368 | DBMET02368 | |
| 0.008 | 0.759 | 0.149 | UDP-glucose 4-epimerase inhibitor | 0.149 0.029 DBMET02368 | DBMET02368 | |
| 0.005 | 0.757 | 0.078 | Androgen antagonist | 0.078 0.068 DBMET02368 | DBMET02368 | |
| 0.002 | 0.759 | 0.05 | TRPM8 blocker | 0.05 0.016 DBMET02368 | DBMET02368 | |
| 0.008 | 0.776 | 0.214 | Alpha-N-acetylglucosaminidase inhibitor | 0.214 0.03 DBMET02368 | DBMET02368 | |
| 0.01 | 0.78 | 0.067 | Glutamate (mGluR6) antagonist | 0.067 0.046 DBMET02368 | DBMET02368 | |
| 0.005 | 0.777 | 0.047 | Retinoic acid alpha receptor agonist | 0.047 0.017 DBMET02368 | DBMET02368 | |
| 0.002 | 0.775 | 0.061 | Farnesoid X receptor agonist | 0.061 0.009 DBMET02368 | DBMET02368 | |
| 0.003 | 0.777 | 0.096 | Protein kinase (CK2) inhibitor | 0.096 0.068 DBMET02368 | DBMET02368 | |
| 0.019 | 0.794 | 0.167 | Hexokinase inhibitor | 0.167 0.06 DBMET02368 | DBMET02368 | |
| 0.002 | 0.796 | 0.037 | Liver X receptor alpha agonist | 0.037 0.035 DBMET02368 | DBMET02368 | |
| 0.002 | 0.813 | 0.075 | Biliverdin reductase inhibitor | 0.075 0.029 DBMET02368 | DBMET02368 | |
| 0.004 | 0.849 | 0.044 | Glutamate (mGluR group III) antagonist | 0.044 0.029 DBMET02368 | DBMET02368 | |
| 0.003 | 0.87 | 0.047 | Prostaglandin E2 antagonist | 0.047 0.038 DBMET02368 | DBMET02368 | |
| 0.002 | 0.875 | 0.041 | RNA-directed RNA polymerase inhibitor | 0.041 0.018 DBMET02368 | DBMET02368 | |
| 0.001 | 0.896 | 0.039 | HCV NS5B polymerase inhibitor | 0.039 0.015 DBMET02368 | DBMET02368 | |
| 0.022 | 0.921 | 0.128 | NOS3 expression enhancer | 0.128 0.101 DBMET02368 | DBMET02368 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |